Fiducial Markers Implantation for Prostate Image-guided Radiotherapy: a Report on the Transperineal Approach
Overview
Authors
Affiliations
Introduction: In the external beam prostate cancer radiation therapy, daily gland displacement could lead to a target missing. The use of intra-prostatic gold fiducial markers for daily prostate position verification and correction before and during treatment delivery (image-guided radiotherapy, IGRT) is widely used in the radiation therapy centers to accurately target the prostate. Usually, the fiducial markers are implanted through the rectum, with complications such as infections and rectal bleeding. We report our experience in prostate fiducial markers implantation through a transperineal approach.
Patients And Methods: Between September 2011 and January 2018 at our center, 101 patients underwent gold seed fiducial marker transperineal ultrasound-guided implantation for prostate IGRT. We retrospectively reviewed their features and outcome. Twenty-two (21.8%) patients had previously been subjected to a transurethral prostate resection (TURP) for obstructive urinary symptoms because of benign prostatic hypertrophy. No antibiotic prophylaxis was used.
Results: The procedure was well tolerated. In one patient, a single episode of self-limiting urinary bleeding occurred just after it. No other complication was recorded. All the patients, at the evaluation before discharge, reported no pain or dysuria. No rectal bleeding, hematospermia, urinary obstruction or infection were reported in the next days. No markers lost or migration occurred.
Discussion And Conclusion: According to our experience, prostate fiducial markers implantation through a transperineal approach is safe and should be recommended to limit the use of antibiotic therapy and patients morbidity. A previous TURP was not related to a higher risk of loss of seeds.
Hong S, Bae S, Hwang J, Lee E Ultrasonography. 2024; 43(4):229-237.
PMID: 38898635 PMC: 11222131. DOI: 10.14366/usg.23229.
Mahdavi A, Mofid B, Taghizadeh-Hesary F BMC Med Imaging. 2023; 23(1):79.
PMID: 37308834 PMC: 10262562. DOI: 10.1186/s12880-023-01036-z.
Moll M, Weiss M, Stanisav V, Zaharie A, Goldner G Radiol Oncol. 2023; 57(1):95-102.
PMID: 36653352 PMC: 10039472. DOI: 10.2478/raon-2023-0004.
Multiparametric MRI in the management of prostate cancer: an update-a narrative review.
Ziglioli F, Maestroni U, Manna C, Negrini G, Granelli G, Greco V Gland Surg. 2021; 9(6):2321-2330.
PMID: 33447583 PMC: 7804524. DOI: 10.21037/gs-20-561.
Palumbo P, Manetta R, Izzo A, Bruno F, Arrigoni F, De Filippo M Gland Surg. 2021; 9(6):2235-2247.
PMID: 33447576 PMC: 7804542. DOI: 10.21037/gs-20-547.